BARCELONA, SPAIN / August 11, 2025 / Longevity is experiencing a scientific revolution, yet most consumer products lag behind. While wearables and wellness hacks offer health insights, few rely on validated cellular science - until now. Omniscope, a pioneering TechBio company co-founded by Prof. Holger Heyn, Vijay Vaswani, and Lynnette Ang, is transforming the field with osLongevity, a platform that tracks and optimizes aging through immune system analysis at the cellular level.
With years of expertise in immune profiling and AI-driven analytics - applied to cancer, autoimmunity, vaccines, and transplants - Omniscope recently showcased a GenAI breakthrough, engineering immune cells for scalable, affordable therapies and launched its pioneering osLongevity product. osLongevity redefines healthspan, focusing on years of full physical and cognitive vitality by modeling aging cell by cell. Unlike fragmented data from other tech (e.g., heart rate), it offers a comprehensive aging profile, easily queried like ChatGPT.
At the heart of osLongevity is Immune Age, a dynamic metric reflecting immune health relative to chronological age. Unlike static DNA clocks, it adapts to training, recovery, illness, diet, and interventions, providing a real-time dashboard to track your aging trajectory and guide lifestyle changes.
Omniscope CEO Vijay with FoundersX team (Leo Cui, Andi White, and Sizi Chen) at TechWeek SF 2024
"The immune system is one of the most dynamic and responsive indicators of how we're aging," said Prof. Holger Heyn, Omniscope Co-Founder and CSO. "With osLongevity, we can see the effects of lifestyle and interventions in near real time and guide people toward actions that help preserve health and extend vitality."
Already deployed with elite athletes through a collaboration with FC Barcelona, osLongevity is derived from technology used in clinical trials and peer-reviewed research to optimize athletic performance. The same immune profiling tools that track resilience, inflammation, and recovery in professional sports are now being adapted for broader longevity and healthspan applications, turning cutting-edge immunology into everyday decision-making.
"osLongevity combines deep immune science with practical, personalized insights," said Vijay Vaswani, Omniscope Co-Founder and CEO. "Built on the same platform that has advanced breakthrough immunotherapies, it empowers consumers to see how diet, exercise, sleep, and other lifestyle choices impact their longevity. Importantly, this also gives healthcare professionals a powerful ‘cellular avatar' to deliver truly personalized, data-driven care."
In an industry crowded with guesswork, Omniscope delivers clarity. Aging isn't just a date of birth, or written in your DNA - it's shaped by your immune system every single day. Omniscope's mission is to decode that system and ensure it continues protecting you, just as nature designed it to do.
The company is backed by FoundersX Ventures, a venture capital firm based in Silicon Valley and known for its AI-first investment approach with multiple home runs, as the lead investor at its seed round.
"Omniscope's osLongevity is a big leap in preventive healthcare, harnessing GenAI and high-throughput single-cell TCR sequencing to track immune age in real time. By empowering individuals to understand how lifestyle impacts their biological aging, osLongevity puts the power of everyone's health in his or her own hands, paving the way for a future where staying young and healthy is a choice driven by data and science." said Helen Liang, PhD., Founder & Managing Partner of FoundersX Ventures.
About Omniscope
Omniscope is a pioneering TechBio company decoding the immune system to transform human health. Using proprietary immune profiling and AI-powered analytics, Omniscope delivers validated insights across oncology, autoimmune disease, infectious disease, and now longevity. Founded in 2020, the company partners with leading organizations to translate immune intelligence into action. Learn more at www.omniscope.ai.